Seres Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Seres Therapeutics, Inc. (Nasdaq: MCRB) on October 29, 2019. The filing discloses the entry into a material definitive agreement and the creation of a direct financial obligation. Seres is an emerging growth company focused on developing microbiome-based therapies.
Key Financial Metrics and Transaction Details
The Company entered into a Loan and Security Agreement with Hercules Capital, Inc. establishing a Term Loan Facility with the following terms:
- Total Facility Size: Up to $50.0 million in aggregate principal.
- Initial Funding: $25.0 million advanced on the Closing Date (October 29, 2019).
- Tranche Structure:
- Tranche 1: $25.0 million (funded).
- Tranche 2: Up to $12.5 million available upon milestone satisfaction through March 15, 2021.
- Tranche 3: Up to $12.5 million available upon Hercules approval on or prior to June 30, 2021.
- Interest Rate: The greater of (i) Prime Rate + 4.40% or (ii) 9.65%.
- Repayment Terms: Interest-only payments through December 1, 2021 (extendable to June 1, 2022 upon milestones). Principal and interest repaid in equal monthly installments thereafter through November 1, 2023.
- Upfront Costs: $375,000 commitment fee paid on the Closing Date.
- Prepayment Premium: 3.0% (Year 1), 2.0% (Year 2), or 1.0% (Post-Year 2) of prepaid amounts.
- End of Term Charge: 4.85% of the aggregate funded amount upon full repayment.
- Collateral: Secured by substantially all Company assets, excluding intellectual property.
Material Changes and Covenants
This transaction represents a significant increase in the Company's debt obligations. The agreement includes affirmative and negative covenants, including restrictions on incurring additional indebtedness, mergers, acquisitions, and asset sales. Notable exceptions allow the Company to issue up to $150 million in convertible notes and enter into exclusive outbound licenses for intellectual property.
A liquidity covenant commences on October 31, 2020, or December 31, 2020, depending on milestone satisfaction. However, if the Company's market capitalization exceeds $350 million, the liquidity covenant is waived.
Outlook, Risks, and Contingencies
The filing does not provide specific revenue guidance or management commentary on future financial performance beyond the loan terms. Key risks associated with this agreement include:
- Events of Default: Include insolvency, failure to pay debts, covenant breaches, material adverse effects, and material misrepresentations. Default allows Hercules to demand immediate repayment and exercise remedies against collateral.
- Milestone Dependency: Access to the remaining $25.0 million and the extension of the interest-only period are contingent on satisfying specific milestones.
- Asset Restrictions: The Company cannot pledge its intellectual property to other lenders.
Investor Verification Checklist
- Verify the Company's current cash position and burn rate to assess runway with the new debt service obligations.
- Review the specific performance milestones required to unlock Tranches 2 and 3 and extend the interest-only period.
- Confirm the Company's current market capitalization to determine if the liquidity covenant is currently applicable.
- Examine the full text of the Loan and Security Agreement (Exhibit 10.1) for detailed definitions of "Material Adverse Effect" and specific covenant exceptions.
- Assess the impact of the 4.85% end-of-term charge on the total cost of capital.